



First Patients Enrolled at SENTA Partners in the US

Melbourne, Australia – 21 November 2023: Adherium Limited (ASX: ADR), a leading digital health company specialising in remote patient monitoring and data solutions for respiratory patients, confirms the first patients have been enrolled and remote patient monitoring underway as part of the SENTA's commercial roll out of the Hailie® platform.

In September Adherium entered a partnership with SENTA (Southern Ear, Nose, Throat and Allergy), one of the largest, premier specialty allergy and asthma medical groups in the United States. The first patients are now being monitored and managed at SENTA clinics in Atlanta, Georgia.

Enrollment will expand and scale to more patients and providers into 2024 within SENTA's 48 locations in six states with 88 specialist allergy, asthma and ENT physicians, physician assistants and nurse practitioners.

Hailie's FDA 510(k) cleared advanced, drug agnostic sensors are the first to measure inhaler use and inspiratory flow rate. Adherium's state-of-the-art Hailie sensor technology and software platform empower patients and their doctors with information to improve adherence, reduce exacerbations and improve quality of life.

Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium is paid for sensor sales and receives monthly, per patient fees for generating and transmitting respiratory data.

Enquiries:

Rick Legleiter

CEO

Adherium Limited

investors@adherium.com

Rudi Michelson

Monsoon Communications

rudim@monsoon.com.au

-ENDS-

Authorised for release by the Board of Directors

About Adherium

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>

About the Hailie Platform

Adherium's proprietary Hailie® platform is transforming the management of chronic respiratory conditions including asthma and chronic obstructive pulmonary disease.

Hailie's cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient's prescribed inhaler. With a user-friendly app, a patient can receive, act on and share their personal information and data reports with doctors and carers.

Hailie's growing portfolio of sensors have been cleared by the FDA and approved by the TGA, EU and UK. The clinically proven sensors remotely capture when and how an inhaler is being used through key physiological parameters including inhalation flow rate, anywhere people live, work and study.

The Hailie solution creates and delivers data supporting far better patient medication adherence, behavioural influencing, escalations and interventions to improve health outcomes and self-management by patients. The Hailie platform drives health costs down by reducing hospital admissions and enables doctors to bill for remote patient management.

Independent studies show the Hailie platform increases medication adherence by 180% in children with an associated 80% reduction in hospital admissions. Hailie has been shown to increase adherence by 59% in adults with a reduction in severe exacerbations of 61%.